Hypertrophic Cardiomyopathy (HCM) remains underdiagnosed and inconsistently managed despite advances in diagnostics and therapeutics. Clinicians often face challenges in early recognition, differentiating HCM from similar conditions, and applying evolving risk stratification and treatment strategies. Traditional therapies may provide limited symptom relief, and the integration of newer disease-modifying agents, such as cardiac myosin inhibitors (CMIs), continues to evolve.
During this live, interactive webcast, Dr. Theodore Abraham and Dr. Martin Maron will address these challenges through real-world patient scenarios, aiming to improve the recognition, diagnosis, and management of HCM.
Attend the live webcast to claim AMA/ABS/ANCC/ACPE credit after completion of the brief Post-Test Evaluation.